Table 4.
Assessment of therapy control of male and female patients with CAH
| Variable | Men with CAH | Women with CAH |
|---|---|---|
| (n = 30) (%) | (n = 29) (%) | |
| AUC 17OHP | ||
| Within reference range | 13 (43.3) | 15 (51.7) |
| Above reference range | 16 (53.3) | 12 (41.4) |
| Below reference range | 1 (3.3) | 2 (6.9) |
| AUC A4 | ||
| Within reference range | 24 (80.0) | 24 (82.8) |
| Above reference range | 6 (20.0) | 1 (3.4) |
| Below reference range | NA | 4 (13.8) |
| AUC T | ||
| Within reference range | 20 (96.7) | 29 (100.0) |
| Above reference range | 1 (3.3) | NA |
| Below reference range | NA | NA |
| AUC A4/T ratio | 0.7-2.8 | 0.7-17.7 |
| Within reference range | 20 (66.7) | 28 (96.6) |
| Out of reference range | 7 (23.3) | NA |
| Below reference range | 3 (10.0) | 1 (3.4) |
Presentation of values as n (%).
Abbreviations: 17OHP, 17-hydroxyprogesterone; A4, androstenedione; AUC, area under the curve; CAH, congenital adrenal hyperplasia; NA, not available; T, testosterone.